Intellectual Property (Patent Law)

Association for Molecular Pathology v. Myriad Genetics, Inc. — Study Notes

569 U.S. 576 (2013)

Study notes for Association for Molecular Pathology v. Myriad Genetics, Inc.: professor notes, cold call prep, exam angles, and memory aids.

Naturally occurring DNA segments are unpatentable as products of nature, while cDNA may be patentable as it is synthetically created.
Professor Notes

This case is pivotal in defining the boundaries of patent eligibility under 35 U.S.C. § 101, particularly concerning natural phenomena and synthetic biology. Myriad Genetics' attempt to patent isolated segments of DNA, specifically the BRCA1 and BRCA2 genes, which are linked to hereditary breast and ovarian cancer, raises significant questions about the implications of patenting naturally occurring substances. Professors often emphasize the Court's rationale in distinguishing between natural DNA segments and synthetic cDNA, highlighting the importance of human intervention in the patent process. This case showcases the balance between encouraging innovation in biotechnology and preserving access to fundamental biological constructs essential for public health and scientific advancement.

Cold Call Prep
  1. 1What was the primary issue in Association for Molecular Pathology v. Myriad Genetics, Inc.?
  2. 2Explain the Court's rationale for denying patent eligibility to naturally occurring DNA.
  3. 3What distinguishes cDNA from naturally occurring DNA in terms of patent eligibility?
  4. 4How does this case relate to the broader concept of products of nature in patent law?
  5. 5What implications does this decision have for future biotechnology patents?
  6. 6Describe how this ruling affects access to genetic testing for patients.
  7. 7Can you provide examples of other applications of gene patenting outside this case?
Mnemonic Device

DNA is a natural phenomenon, cDNA is a man-made creation.

Distinguish From
CaseDistinction
Diamond v. ChakrabartyIn Chakrabarty, the Court permitted the patenting of a genetically engineered microorganism because it was a human-made invention, unlike Myriad's naturally isolated DNA.
Mayo Collaborative Services v. Prometheus Laboratories, Inc.Mayo ruled that simply discovering a law of nature with an application does not make it patentable, reinforcing principles seen in Myriad regarding products of nature.
Amgen Inc. v. SanofiAmgen focused on the sufficiency of disclosures in patent applications rather than the eligibility of natural products, contrasting with Myriad's focus on the nature of the genetic material itself.
Policy Arguments

For the Rule

Preventing the patenting of naturally occurring substances ensures that fundamental biological tools remain accessible for research and public benefit, promoting innovation in the scientific community.

Against the Rule

Limiting patent eligibility may disincentivize investment in genetic research and development, ultimately hindering advances in medical treatments and diagnostics.

Class Discussion Points
  • Debate the ethical implications of gene patenting on public health.
  • Consider how this ruling impacts the financial models of biotech companies.
  • Discuss potential future challenges in patent law related to synthetic biology and genetic engineering.
  • Evaluate the Court's interpretation of the 'products of nature' doctrine.
  • Explore how similar legal principles apply to other areas of scientific discovery, such as pharmaceuticals.
Exam Angle

This case frequently appears on exams as an illustration of the application of patentability standards to biotechnology and the significance of the product of nature doctrine. Students should be prepared to analyze the Court's reasoning and its impact on future patentability in the biological sciences.

View Full Case Brief

Ace Your Cold Calls with Briefly

Get AI-powered case briefs, study notes, and cold call prep for every case in your casebook.